Objectives

After participating in this educational activity, attendees should be able to:

1|Describe a patient’s path from an abnormal screening CT through diagnosis, treatment and survivorship, including the patient’s experience at each step.
2|Compare the safety and survival of today’s minimally invasive surgery for screen-detected lung cancer with the outcomes in the early screening trials.
3|Identify opportunities to increase lung cancer screening at Baystate, and beyond that addresses multi-level barriers.
 
Presenter(s): 
Eduardo R. Núñez, MD, MS
Panelist
Matthew Deluzio, DO, FACS
 
NameRoleFinancial Relationship DisclosuresDiscussion of
Unlabeled/Unapproved Uses of
Drugs/Devices in Presentation?
 Eduardo R. Núñez, MD, MS 

 Speaker 

No relevant relationships with ineligible companies to disclose no
Matthew Deluzio, DO, FACSPanelist
No relevant relationships with ineligible companies to disclose  
no
    
Session date: 
11/11/2026 - 8:00am to 9:00am EST
Location: 
Hybrid
759 Chestnut Street
Springfield, MA 01199
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AAPA Category 1 CME credit
    Baystate Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PA’s should only claim credit commensurate with the extent of their participation.
  • 1.00 ACPE Contact Hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC Contact Hours
  • 1.00 IPCE Credit Hour(s)
Please login or register to take this course.